Soluble Syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

Richard Lovell; Janet Dunn; Gulnaz Begum; Nicola Newnham; Timothy Plant; Paul Moss; Mark Drayson; Guy Pratt

doi:10.1111/j.1365-2141.2005.05647.x

Soluble Syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

Richard Lovell, Janet Dunn, Gulnaz Begum, Nicola Newnham, Timothy Plant, Paul Moss, Mark Drayson, Guy Pratt

Research output: Contribution to journal › Article

34 Citations (Scopus)

Abstract

Syndecan-1 (CD138) is a heparin sulphate proteoglycan that is over expressed on the surface of both normal and malignant plasma cells and actively shed from the cell surface (soluble syndecan-1). Soluble syndecan-1 has been shown to be an independent prognostic factor in myeloma but its role in prognostic classification requires further investigation. We have retrospectively measured soluble syndecan-1 in 324 presentation samples and 154 plateau phase samples from the UK Medical Research Council Myeloma VIth trial. Log-rank analysis showed that the presentation value of soluble syndecan-1 is a highly significant prognostic factor when assessing survival from entry (chi2=14.92, P

Original language	English
Pages (from-to)	542-548
Number of pages	7
Journal	British Journal of Haematology
Volume	130
DOIs	https://doi.org/10.1111/j.1365-2141.2005.05647.x
Publication status	Published - 1 Aug 2005

Keywords

multiple myeloma
prognostic factors

Access to Document

10.1111/j.1365-2141.2005.05647.x

Cite this

@article{c5cd14cae7de4209bf726a1bab816257,

title = "Soluble Syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival",

abstract = "Syndecan-1 (CD138) is a heparin sulphate proteoglycan that is over expressed on the surface of both normal and malignant plasma cells and actively shed from the cell surface (soluble syndecan-1). Soluble syndecan-1 has been shown to be an independent prognostic factor in myeloma but its role in prognostic classification requires further investigation. We have retrospectively measured soluble syndecan-1 in 324 presentation samples and 154 plateau phase samples from the UK Medical Research Council Myeloma VIth trial. Log-rank analysis showed that the presentation value of soluble syndecan-1 is a highly significant prognostic factor when assessing survival from entry (chi2=14.92, P",

keywords = "multiple myeloma, prognostic factors",

author = "Richard Lovell and Janet Dunn and Gulnaz Begum and Nicola Newnham and Timothy Plant and Paul Moss and Mark Drayson and Guy Pratt",

year = "2005",

month = aug,

day = "1",

doi = "10.1111/j.1365-2141.2005.05647.x",

language = "English",

volume = "130",

pages = "542--548",

journal = "British Journal of Haematology",

issn = "1365-2141",

publisher = "Wiley",

}

TY - JOUR

T1 - Soluble Syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

AU - Lovell, Richard

AU - Dunn, Janet

AU - Begum, Gulnaz

AU - Newnham, Nicola

AU - Plant, Timothy

AU - Moss, Paul

AU - Drayson, Mark

AU - Pratt, Guy

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Syndecan-1 (CD138) is a heparin sulphate proteoglycan that is over expressed on the surface of both normal and malignant plasma cells and actively shed from the cell surface (soluble syndecan-1). Soluble syndecan-1 has been shown to be an independent prognostic factor in myeloma but its role in prognostic classification requires further investigation. We have retrospectively measured soluble syndecan-1 in 324 presentation samples and 154 plateau phase samples from the UK Medical Research Council Myeloma VIth trial. Log-rank analysis showed that the presentation value of soluble syndecan-1 is a highly significant prognostic factor when assessing survival from entry (chi2=14.92, P

AB - Syndecan-1 (CD138) is a heparin sulphate proteoglycan that is over expressed on the surface of both normal and malignant plasma cells and actively shed from the cell surface (soluble syndecan-1). Soluble syndecan-1 has been shown to be an independent prognostic factor in myeloma but its role in prognostic classification requires further investigation. We have retrospectively measured soluble syndecan-1 in 324 presentation samples and 154 plateau phase samples from the UK Medical Research Council Myeloma VIth trial. Log-rank analysis showed that the presentation value of soluble syndecan-1 is a highly significant prognostic factor when assessing survival from entry (chi2=14.92, P

KW - multiple myeloma

KW - prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=24944526709&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05647.x

DO - 10.1111/j.1365-2141.2005.05647.x

M3 - Article

C2 - 16098068

SN - 1365-2141

VL - 130

SP - 542

EP - 548

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Soluble Syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

Abstract

Keywords

Access to Document

Fingerprint

Cite this